Dihexa: research

Dihexa dosage

Typical reported dose: 10 mg under the tongue twice a week

• 10 mg twice weekly: 10 mg under the tongue twice weekly twice weekly, under the tongue. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
• Five daily doses, then weekly: 15 mg daily for 5 days, then 20 mg once weekly daily for 5 days, then once weekly, under the tongue. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
• 5-10 mg weekly report: 5-10 mg once weekly once weekly, by mouth. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
• 20 mg daily, planned breaks: 20 mg daily daily, by mouth. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
• 10 mg, then 5 mg: 10 mg every other day for 1 week, then reduced to 5 mg every other day initially; later frequency not restated, by mouth. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
• Skin application every 3-5 days: 15-30 mg in a DMSO preparation every 3-5 days every 3-5 days, skin patch. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Dihexa side effects and risks

Reported side effects

• Changes in behavior or face recognition: One report described more rigid routines and worse face recognition; no incidence estimate., moderate. Stop and discuss new changes with a clinician. Other medicines confound the report. (source)
• Sleepiness or exhaustion: A commenter reported exhaustion about 2 hours after oral 8 mg and again after 4 mg., moderate. Avoid driving when sleepy; seek review of new or persistent symptoms. (source)
• Overfocus and emotional dulling: Reported with oral 50 mg plus stimulants; no causal attribution or rate is possible., moderate (source)
• Allergy or infection related to the product: General unapproved product risk, not a measured dihexa event rate., serious. Breathing problems or spreading injection-site infection need urgent care. (source)

Stop and get help if

• Trouble breathing, throat or tongue swelling, collapse or fainting after exposure.: Call emergency services now. These can be signs of anaphylaxis.
• A hot, painful, spreading red injection site, especially with fever or feeling very ill.: Seek urgent medical care. Confusion, fainting or fast breathing needs emergency care.

Who should avoid it

• pregnant: Precautionary block: no pregnancy safety data for directly taking dihexa.
• breastfeeding: Precautionary block: milk transfer and infant effects are unknown.
• tryingToConceive: Precautionary block: fertility and early-pregnancy safety are unknown.
• under18: Precautionary block: no pediatric dosing or developmental safety data.
• activeCancer: Proposed HGF/MET growth signaling raises a theoretical cancer-growth concern. No safe exposure is established.
• cancerHistory: Discuss prior cancer or unexplained new lumps with the treating clinician; the possible growth-signaling risk is unquantified.
• psychiatricCondition: Anecdotes include behavior changes. Existing psychiatric illness and psychoactive-drug combinations need review.
• kidneyDisease: No direct-dihexa human clearance data or kidney-dose adjustment is established.
• liverDisease: No direct dihexa human metabolism data or liver-dose adjustment is established.
• testedAthlete: Unapproved pharmacological substances are prohibited under the 2026 List; growth-factor rules may also apply.

Interactions

• Other nootropics and psychoactive drugs: No interaction studies establish safe combinations. Stimulant and nootropic stacks confound reports of mood, sleep and focus changes.

Product quality risks

• General peptide warnings describe wrong ingredients, wrong amounts and microbial or solvent contamination. No independent market survey of this compound was located.
• A purity percentage cannot establish dose, identity, sterility or clinical safety.
• Research-use labeling does not mean a product meets medicine quality standards.

How Dihexa works

It was designed to help nerve cells connect through HGF and MET growth signals. Early papers carry retraction and concern notices. Later rat findings and related fosgonimeton trials do not establish human benefits from taking dihexa.

• HGF/MET growth signaling: Proposed increase in nerve-cell connections. The foundational mechanism evidence is disputed.
• PI3K/AKT signaling: Changed in a mouse study; this does not prove a direct drug target in people.

Half-life: Unknown after direct dosing in humans. Long rat estimates come from a paper with a notice of concern.